NO993520L - Doseringsformer og fremgangsmÕte for Õ bedre erektil dysfunksjon - Google Patents

Doseringsformer og fremgangsmÕte for Õ bedre erektil dysfunksjon

Info

Publication number
NO993520L
NO993520L NO993520A NO993520A NO993520L NO 993520 L NO993520 L NO 993520L NO 993520 A NO993520 A NO 993520A NO 993520 A NO993520 A NO 993520A NO 993520 L NO993520 L NO 993520L
Authority
NO
Norway
Prior art keywords
erectile dysfunction
better
methods
dosage forms
active ingredient
Prior art date
Application number
NO993520A
Other languages
English (en)
Norwegian (no)
Other versions
NO993520D0 (no
Inventor
Edward Stewart Johnson
Anthony Clarke
Richard David Green
Original Assignee
Scherer Ltd R P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scherer Ltd R P filed Critical Scherer Ltd R P
Publication of NO993520D0 publication Critical patent/NO993520D0/no
Publication of NO993520L publication Critical patent/NO993520L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/48Ergoline derivatives, e.g. lysergic acid, ergotamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
NO993520A 1997-01-17 1999-07-16 Doseringsformer og fremgangsmÕte for Õ bedre erektil dysfunksjon NO993520L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9700878.3A GB9700878D0 (en) 1997-01-17 1997-01-17 Dosage forms and method for ameliorating male erectile dysfunction
PCT/GB1998/000143 WO1998031368A1 (en) 1997-01-17 1998-01-16 Dosage forms and method for ameliorating male erectile dysfunction

Publications (2)

Publication Number Publication Date
NO993520D0 NO993520D0 (no) 1999-07-16
NO993520L true NO993520L (no) 1999-09-16

Family

ID=10806104

Family Applications (1)

Application Number Title Priority Date Filing Date
NO993520A NO993520L (no) 1997-01-17 1999-07-16 Doseringsformer og fremgangsmÕte for Õ bedre erektil dysfunksjon

Country Status (27)

Country Link
US (2) US6342246B2 (ru)
EP (1) EP0954314B1 (ru)
JP (1) JP2000513736A (ru)
KR (1) KR100416768B1 (ru)
CN (1) CN1243440A (ru)
AT (1) ATE211385T1 (ru)
AU (1) AU717337B2 (ru)
BG (1) BG103570A (ru)
BR (1) BR9808888A (ru)
CA (1) CA2276758A1 (ru)
DE (1) DE69803360T2 (ru)
DK (1) DK0954314T3 (ru)
EE (1) EE03805B1 (ru)
ES (1) ES2167061T3 (ru)
GB (1) GB9700878D0 (ru)
HU (1) HUP0001089A3 (ru)
IL (1) IL130714A0 (ru)
NO (1) NO993520L (ru)
NZ (1) NZ336436A (ru)
PL (1) PL334656A1 (ru)
PT (1) PT954314E (ru)
RU (1) RU2204413C2 (ru)
SK (1) SK283301B6 (ru)
TR (1) TR199901669T2 (ru)
UA (1) UA62954C2 (ru)
WO (1) WO1998031368A1 (ru)
YU (1) YU33099A (ru)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US6121276A (en) * 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
GB9813278D0 (en) * 1998-06-20 1998-08-19 Medical Res Council Male contraceptive
JP2000178204A (ja) * 1998-10-05 2000-06-27 Eisai Co Ltd ホスフォジエステラ―ゼ阻害剤を含有する口腔内速崩壊性錠剤
CA2251255A1 (en) * 1998-10-20 2000-04-20 Mcgill University The use of dopaminergic agents in the management of sexual dysfunction
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
CZ20023637A3 (cs) 2000-04-07 2003-02-12 Tap Pharmaceutical Products, Inc. Deriváty apomorfinu a způsoby jejich použití
SE0102036D0 (sv) * 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
SE0002934D0 (sv) 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
EP1315502B1 (en) * 2000-08-30 2010-03-17 Unimed Pharmaceuticals, LLC Method for treating erectile dysfunction and increasing libido in men
US20020103105A1 (en) * 2000-11-22 2002-08-01 Brioni Jorge D. Use of selective dopamine D4 receptor agonists for treating sexual dysfunction
US20030008878A1 (en) * 2001-03-09 2003-01-09 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
US7022728B2 (en) 2001-03-09 2006-04-04 Abbott Laboratories Benzimidazoles that are useful in treating male sexual dysfunction
US20020169166A1 (en) * 2001-03-09 2002-11-14 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
US6960589B2 (en) 2001-03-09 2005-11-01 Abbott Laboratories Benzimidazoles that are useful in treating sexual dysfunction
FR2834894B1 (fr) * 2002-01-21 2004-02-27 Servier Lab Composition pharmaceutique orodispersible de piribedil
FR2834897B1 (fr) * 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible de testosterone
WO2003080030A1 (en) * 2002-03-26 2003-10-02 Bernard Charles Sherman Stable tablets comprising pergolide mesylate
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
US20040156894A1 (en) * 2003-02-07 2004-08-12 Grother Leon Paul Use of edible acids in fast-dispersing pharmaceutical solid dosage forms
MXPA05010450A (es) * 2003-03-31 2005-11-04 Titan Pharmaceuticals Inc Dispositivo polimerico implantable para la liberacion prolongada de agonistas de dopamina.
US20050137265A1 (en) * 2003-03-31 2005-06-23 Haley Eugene T. Rapidly dissolving metoclopramide solid oral dosage and method thereof
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
WO2005021056A1 (en) * 2003-08-21 2005-03-10 Cns, Inc. Effervescent delivery system
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
US8241664B2 (en) 2005-04-15 2012-08-14 Clarus Therapeutics, Inc Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
SI1937276T1 (sl) 2005-10-12 2013-04-30 Unimed Pharmaceuticals, Llc C/O Abbott Laboratoires 100 Abbott Park Road Izboljšani testosteronski gel in postopek uporabe
US20080014228A1 (en) * 2006-07-14 2008-01-17 Olivia Darmuzey Solid form
US20080311162A1 (en) * 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
US8741918B2 (en) 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
EP2257220B1 (en) * 2008-03-13 2017-06-14 Liebel-Flarsheim Company LLC Multi-function, foot-activated controller for imaging system
US20100168119A1 (en) * 2008-11-05 2010-07-01 Pharmorx, Inc. Compositions and methods for minimizing or reducing agonist-induced desensitization
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
US8545879B2 (en) 2009-08-31 2013-10-01 Wilmington Pharmaceuticals, Llc Fast disintegrating compositions of meloxicam
TR201902233T4 (tr) 2009-10-30 2019-03-21 Ix Biopharma Ltd Hızlı çözünen katı dozaj formu.
CN101797260B (zh) * 2009-12-23 2011-09-21 济南圣泉唐和唐生物科技有限公司 L-阿拉伯糖在制备用于治疗阴茎勃起障碍药物中的用途
AR083361A1 (es) * 2010-10-08 2013-02-21 Scherer Technologies Inc R P Forma de dosificacion de rapida disolucion de vacuna oral utilizando almidon
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
DK2854764T3 (en) * 2012-06-05 2019-04-08 Neuroderm Ltd COMPOSITIONS CONTAINING APOMORPHINE AND ORGANIC ACIDS, AND APPLICATIONS THEREOF
US20150342946A1 (en) 2013-01-30 2015-12-03 Pharmorx Therapeutics, Inc. Treatments For Depression And Other Diseases With A Low Dose Agent
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3928566A (en) * 1970-08-14 1975-12-23 Du Pont Lyophilized biological products
US4098802A (en) * 1975-02-18 1978-07-04 Akzona Incorporated Oral pharmaceutical preparation having androgenic activity
GB1548022A (en) * 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US4877774A (en) * 1987-09-09 1989-10-31 The United States Of America As Represented By The Department Of Health And Human Services Administration of steroid hormones
US5135752A (en) * 1988-10-14 1992-08-04 Zetachron, Inc. Buccal dosage form
HUT75616A (en) * 1992-03-17 1997-05-28 Pfizer Method for prooucing porous delivery devices
CN1139877A (zh) * 1994-01-27 1997-01-08 俄克拉何马大学董事会 迅速溶解的口服药剂形式
US5576014A (en) * 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
ATE189121T1 (de) * 1994-04-22 2000-02-15 Pentech Pharmaceuticals Inc Sublinguale dosierungsformen enthaltend apomorphin zur verwendung bei der behandlung von erektiler dysfunktion
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions

Also Published As

Publication number Publication date
PT954314E (pt) 2002-06-28
KR100416768B1 (ko) 2004-01-31
US20020156056A1 (en) 2002-10-24
DE69803360D1 (de) 2002-02-28
SK97299A3 (en) 2000-11-07
PL334656A1 (en) 2000-03-13
HUP0001089A2 (hu) 2000-11-28
RU2204413C2 (ru) 2003-05-20
IL130714A0 (en) 2000-06-01
CA2276758A1 (en) 1998-07-23
EP0954314A1 (en) 1999-11-10
NO993520D0 (no) 1999-07-16
SK283301B6 (sk) 2003-05-02
EE03805B1 (et) 2002-08-15
CN1243440A (zh) 2000-02-02
US6342246B2 (en) 2002-01-29
EE9900288A (et) 2000-02-15
WO1998031368A1 (en) 1998-07-23
JP2000513736A (ja) 2000-10-17
DK0954314T3 (da) 2002-02-18
BG103570A (bg) 2000-04-28
TR199901669T2 (xx) 2000-07-21
DE69803360T2 (de) 2002-10-10
EP0954314B1 (en) 2002-01-02
AU717337B2 (en) 2000-03-23
KR20000070264A (ko) 2000-11-25
US20010018069A1 (en) 2001-08-30
ES2167061T3 (es) 2002-05-01
ATE211385T1 (de) 2002-01-15
HUP0001089A3 (en) 2001-03-28
UA62954C2 (en) 2004-01-15
NZ336436A (en) 2000-07-28
GB9700878D0 (en) 1997-03-05
YU33099A (sh) 2002-06-19
AU5671098A (en) 1998-08-07
BR9808888A (pt) 2000-10-03

Similar Documents

Publication Publication Date Title
NO993520L (no) Doseringsformer og fremgangsmÕte for Õ bedre erektil dysfunksjon
RU99117926A (ru) Лекарственные формы и способ лечения расстройства мужской эректильной функции
MX2007015480A (es) Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada.
UA84266C2 (ru) Дозированная врачебная форма в виде таблетки или гранулы для перорального введения, которая содержит ингибитор pde 4 и поливинилпиролидон, способы ее получения и применения
EP1708685A4 (en) GALENIC FORMS OF EFFERVESCENT ORAL OPIATES AND METHODS OF ADMINISTERING OPIATES
WO2004112711A3 (en) Oral extended-release composition
HUP0203733A2 (en) Flat medicinal preparation for transmucosal administration of oxycodon or a comparable active ingredient in the oral cavity, for use in pain therapy and in addiction therapy
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
UA90858C2 (ru) Композиция с контролируемым высвобождением варденафила
SE0102276D0 (sv) Device and method for the administration of a medicament
TW200503782A (en) New formulations and use thereof
ATE287264T1 (de) Oral anzuwendende buprenorphinhaltige arzneimittel
AU9551201A (en) Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic diseasestates
ATE262893T1 (de) Darreichungsformen zur behandlung von oralen mykosen
AR034142A1 (es) Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion
HUP0203148A2 (hu) Mirtazapint tartalmazó orálisan dezintegrálódó készítmény
HUP0402358A2 (hu) Szelektív dopamin D4 receptor agonisták alkalmazása szexuális diszfunkciók kezelésére alkalmas gyógyszerkészítmény előállítására
SG145717A1 (en) Composition for releasing a weak base for an extended period of time
ES2188513T3 (es) Utilizacion de desoxipeganina para el tratamiento de la drogodependencia.
MY139719A (en) Oral dosage form for controlled drug release
MY141008A (en) Oral formulations of deoxypeganine and their uses
PE20011042A1 (es) Uso de glutamina para la prevencion de diarrea de inicio tardio inducida por irinotecan
ECSP982396A (es) Composiciones que contienen tetrahidrolipstatina
BG104064A (en) Medicamentous form with controlled release of poorly soluble basic medicamentous forms
ECSP003607A (es) Formulaciones farmaceuticas en capsulas de hidroxipropilmetilcelulosa